Oral anticoagulation in patients with acute heart failure

Key Points

• The research evaluates the impact of oral anticoagulation on mortality and thromboembolic events in patients with acute heart failure.
• Randomized trial design
• Inclusion of patients with acute heart failure
• Comparison between anticoagulation therapy and standard care
• Patients receiving oral anticoagulation experienced a reduction in thromboembolic events by 30% (OR 0.70, 95% CI 0.50-0.95, P=0.02).
• Reduction in all-cause mortality observed, with a rates of 15% in the anticoagulation group vs. 22% in standard care (HR 0.67, 95% CI 0.50-0.90, P=0.01).